本文關(guān)鍵詞： 兔舌VX-2鱗癌 艾迪注射液 紫杉醇注射液 聯(lián)合化療 調(diào)節(jié)性T細(xì)胞　出處：《遵義醫(yī)學(xué)院》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:探討艾迪注射液聯(lián)合紫杉醇注射液化療對兔舌VX-2鱗癌模型中調(diào)節(jié)性T細(xì)胞及其相關(guān)細(xì)胞因子IL-10、IL-35、TGF-β的影響。方法:建立48只兔舌VX-2鱗癌模型,隨機分成4組,再選擇健康兔24只,隨機分成2組,共6組:A組(健康兔+生理鹽水)、B組(健康兔+艾迪注射液)、C組(荷瘤兔+生理鹽水)、D組(荷瘤兔+紫杉醇注射液)、E組(荷瘤兔+艾迪注射液)、F組(荷瘤兔+紫杉醇注射液+艾迪注射液)。建模后第15天開始分組用藥,均通過兔耳緣靜脈給藥,在建模后第14天(用藥前1天)、第22天、第29天均采集兔外周血,第22天各組分別隨機處死6只實驗兔并收集標(biāo)本,第29天各組分別處死剩下的6只實驗兔并收集標(biāo)本。用HE染色法觀察荷瘤兔舌癌癌灶的組織學(xué)形態(tài),FCM檢測各組實驗兔外周血、頸淋巴結(jié)、舌癌原發(fā)灶、癌周組織的CD4+CD25+CD127low Treg/CD4+T細(xì)胞比例,ELISA檢測血清的IL-10、IL-35、TGF-β濃度。結(jié)果:(1)B組的外周血、頸淋巴結(jié)Treg細(xì)胞比例以及血清的IL-10、IL-35、TGF-β濃度在用藥前、用藥后1周、2周與A組相比均無統(tǒng)計學(xué)差異(P0.05)。(2)C、D、E、F與A組比較:用藥前,僅外周血的Treg細(xì)胞比例和血清的IL-35濃度,C、D、E、F均高于A組(P0.05)。用藥后1周,外周血的Treg細(xì)胞比例和血清的IL-35、TGF-β濃度,C、D、E、F均高于A組(P0.05),而頸淋巴結(jié)的Treg細(xì)胞比例,僅C、D兩組高于A組(P0.05),血清的IL-10濃度,僅C、D、E三組高于A組(P0.05)。用藥后2周,外周血的Treg細(xì)胞比例和血清的IL-35濃度,C、D、E、F均高于A組(P0.05),而頸淋巴結(jié)的Treg細(xì)胞比例和血清的TGF-β濃度,僅C、D、E三組高于A組(P0.05),血清的IL-10濃度,僅C、D兩組高于A組(P0.05)。(3)C、D、E、F四組間兩兩比較:用藥后1周,荷瘤兔外周血、頸淋巴結(jié)的Treg細(xì)胞比例以及血清的IL-10、IL-35、TGF-β的濃度,D、E、F三組均低于C組(P0.05),D、E、F三組間兩兩相比均無統(tǒng)計學(xué)差異(P0.05)。用藥后2周,D組與C組比較,僅血清IL-10濃度低于C組(P0.05);E組與C組比較,除舌癌原發(fā)灶的Treg細(xì)胞比例與C組無統(tǒng)計學(xué)差異(P0.05),其余指標(biāo)均低于C組(P0.05),與D組相比,僅頸淋巴結(jié)的Treg細(xì)胞比例和血清IL-10濃度低于D組(P0.05);F組與C組比較,所有指標(biāo)均低于C組(P0.05),與D組比較,除舌癌原發(fā)灶的Treg細(xì)胞比例與D組無統(tǒng)計學(xué)差異(P0.05),其余指標(biāo)均低于D組(P0.05),與E組比較,僅血清TGF-β的濃度低于E組(P0.05)。(4)各組頸淋巴結(jié)、舌癌原發(fā)灶、癌周組織的Treg細(xì)胞比例在用藥后1周(T1)與用藥后2周(T2)組內(nèi)比較:頸淋巴結(jié)與癌周組織僅C、D兩組T2高于T1(P0.05),舌癌原發(fā)灶C、D、E、F四組T1與T2均無統(tǒng)計學(xué)差異(P0.05)。(5)實驗兔血清的IL-10、IL-35、TGF-β濃度均與外周血的Treg細(xì)胞比例呈正相關(guān)(0.5r1,P0.01)。結(jié)論:艾迪注射液聯(lián)合紫杉醇注射液化療可抑制兔舌VX-2鱗癌模型中外周血、舌癌原發(fā)灶、舌癌癌周組織、頸淋巴結(jié)的CD4+CD25+CD127low Treg/CD4+T細(xì)胞比例及血清內(nèi)IL-10、IL-35、TGF-β濃度的增高。
[Abstract]:Objective: to investigate the effects of Aidi injection combined with paclitaxel injection chemotherapy on regulatory T cells and their related cytokines IL-10 IL-35 in rabbit tongue VX-2 squamous cell carcinoma model. Methods: 48 rabbit tongue VX-2 squamous cell carcinoma models were established and randomly divided into 4 groups. 24 healthy rabbits were randomly divided into 2 groups. Group B (Aidi injection) group C (normal saline group D) (paclitaxel injection group E (Adi injection rabbit)). Group F (paclitaxel injection Aidi injection) was divided into groups on the 15th day after modeling and was administered via the rabbit ear vein on the 14th day (one day before, 22 days before the use of the drug). On the 29th day, the peripheral blood was collected. On the 22nd day, 6 experimental rabbits were randomly killed and the specimens were collected. On the 29th day, the remaining 6 experimental rabbits were killed and the specimens were collected. The histological morphology of tongue cancer foci was observed by HE staining and the peripheral blood and cervical lymph nodes were detected by FCM in each group. The ratio of CD4 CD25 CD127low Treg/CD4 T cells in peripheral tissues of tongue cancer was detected by Elisa. Results the percentage of Treg cells in peripheral blood, cervical lymph nodes and serum IL-10, IL-35 and TGF- 尾 concentration in group B were 1 week before and 1 week after administration of TGF- 尾. There was no statistical difference between group A and group A in 2 weeks. Compared with group A, only the proportion of Treg cells in peripheral blood and the concentration of IL-35 in serum were compared with those in group A. The percentage of Treg cells in peripheral blood and the concentration of IL-35 TGF- 尾 in peripheral blood were higher than those in group A (P 0.05). The percentage of Treg cells in cervical lymph nodes was higher in group C and D than in group A, and the concentration of serum IL-10 in group C was higher than that in group A. The ratio of Treg cells in peripheral blood and the concentration of IL-35 in serum in group E were higher than those in group A (P 0.05). However, the percentage of Treg cells and the concentration of TGF- 尾 in the cervical lymph nodes were higher in group C than in group A, and the concentration of IL-10 in serum was only C. Comparison of Treg cells in peripheral blood, cervical lymph nodes and serum IL-10 of rabbits with tumor one week after treatment. The concentration of TGF- 尾 in group C was lower than that in group C (P 0.05). There was no significant difference in the concentration of TGF- 尾 between group C and group C (P 0.05). 2 weeks after treatment, there was no significant difference in the concentration of TGF- 尾 between group C and group C (P 0.05). Compared with group C, serum IL-10 concentration in group D was lower than that in group C (P 0.05). Compared with group C, the percentage of Treg cells in group E was not significantly different from that in group C (P 0.05), and the other indexes were lower than those in group C (P 0.05). The proportion of Treg cells and the concentration of serum IL-10 in cervical lymph nodes were lower than those in group D (P 0.05). Compared with group C, all the indexes in group F were lower than those in group C (P0.05A). Compared with group D, there was no significant difference in the proportion of Treg cells except primary focus of tongue cancer between group D and group D (P 0.05). Compared with group E, the serum TGF- 尾 concentration was lower than that in group E (P 0.05, P 0.05, P 0.05, P < 0.05), and the primary focus of tongue cancer in each group was lower than that in group E. The proportion of Treg cells in pericancerous tissue was higher than that in T1 / T1 group and T2 / T2 group: T2 was higher in cervical lymph node and pericancerous tissue than that in T1 + P0. 05). There was no significant difference in T1 and T2 between the four groups (P < 0.05). The concentration of TGF- 尾 was positively correlated with the proportion of Treg cells in peripheral blood. Conclusion: Aidi injection combined with paclitaxel injection chemotherapy can inhibit peripheral blood, primary focus of tongue cancer and tissue around carcinoma of tongue in rabbit tongue VX-2 squamous cell carcinoma model. The percentage of CD4 CD25 CD127low Treg/CD4 T cells in cervical lymph nodes and the concentration of IL-10, IL-35 and TGF- 尾 in serum were increased.
【學(xué)位授予單位】：遵義醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R739.8;R-332

【相似文獻】

相關(guān)期刊論文 前10條

1 李桂香,范曉萍;艾迪注射液在肺癌綜合治療中的療效觀察[J];甘肅科技;2003年11期

2 王麗青,張秀平;中藥艾迪注射液配合化療治療惡性腫瘤30例[J];中國民間療法;2003年02期

3 方艷秋;;艾迪注射液致休克1例[J];解放軍護理雜志;2005年12期

4 朱廣媛;李東華;張樹范;李笑然;;艾迪注射液的臨床研究進展[J];中醫(yī)藥學(xué)報;2010年01期

5 胡黎川;楊秀斐;蘇銀法;白學(xué)敏;;96例腫瘤患者應(yīng)用艾迪注射液的回顧性調(diào)查[J];醫(yī)藥導(dǎo)報;2012年03期

6 楊志銀;滕川;張麗麗;;化療聯(lián)合艾迪注射液治療中晚期非小細(xì)胞肺癌臨床分析[J];中國藥物經(jīng)濟學(xué);2013年S3期

7 黃繼群;艾迪注射液治療晚期腫瘤療效觀察[J];湖北中醫(yī)雜志;2001年10期

8 陳家俊,賴義勤,陳云鶯;艾迪注射液配合化療治療晚期惡性腫瘤31例臨床觀察[J];中醫(yī)藥通報;2002年03期

9 趙興;艾迪注射液配合放、化療治療惡性腫瘤的臨床觀察[J];中國中西醫(yī)結(jié)合雜志;2003年09期

10 羅彪,陸啟峰,張倬彬;艾迪注射液與放化療合用治療惡性腫瘤[J];臨床腫瘤學(xué)雜志;2003年04期

相關(guān)會議論文 前10條

1 黃朝前;陳興華;周江洋;張春菊;;艾迪注射液致血小板減少一例[A];2009年中國藥學(xué)大會暨第九屆中國藥師周論文集[C];2009年

2 藍(lán)倩薇;;1例艾迪注射液致過敏性休克的護理[A];全國腫瘤護理學(xué)術(shù)交流暨專題講座會議論文匯編[C];2006年

3 李曉慧;徐文芳;;一例靜滴艾迪注射液后發(fā)生過敏患者的搶救與護理[A];全國內(nèi)科護理學(xué)術(shù)交流暨專題講座會議論文匯編[C];2002年

4 楊彩平;王曉霞;高啟龍;王紹霞;;艾迪注射液聯(lián)合化療治療晚期惡性腫瘤的護理[A];“河南省腫瘤�？谱o士職業(yè)安全防護及新技術(shù)交流”學(xué)術(shù)會論文集[C];2011年

5 黃朝前;陳興華;周江洋;張春菊;;艾迪注射液致血小板減少一例[A];2010年中國藥學(xué)大會暨第十屆中國藥師周論文集[C];2010年

6 鄒波峰;李康;王沈玉;;艾迪注射液合并化療治療非小細(xì)胞肺癌的臨床觀察[A];第十屆全國中西醫(yī)結(jié)合腫瘤學(xué)術(shù)大會論文匯編[C];2006年

7 李亞娜;;艾迪注射液治療癌性胸腔積液12例臨床觀察[A];二○○八年貴州省醫(yī)學(xué)會呼吸病學(xué)分會學(xué)術(shù)大會暨國家級繼續(xù)教育項目《睡眠呼吸疾病診治進展學(xué)習(xí)班》論文匯編[C];2008年

8 王英保;王秋波;魏麗;;胸腺肽和艾迪注射液聯(lián)合應(yīng)用對晚期肺癌生存期的觀察[A];中華醫(yī)學(xué)會第五屆全國胸部腫瘤及內(nèi)窺鏡學(xué)術(shù)會議論文匯編[C];2011年

9 章汴生;王曉霞;王小平;曲彩琴;張二變;;艾迪注射液治療晚期消化道惡性腫瘤臨床分析[A];山西省抗癌協(xié)會第六屆腫瘤學(xué)術(shù)交流會論文匯編[C];2003年

10 陳琳;;艾迪注射液對肝癌HepG2細(xì)胞放療增敏的研究[A];中華護理學(xué)會全國腫瘤護理學(xué)術(shù)交流暨專題講座會議論文匯編[C];2010年

相關(guān)碩士學(xué)位論文 前10條

1 李喜英;艾迪注射液與康艾注射液聯(lián)合化療用于中老年晚期非小細(xì)胞肺癌（氣陰兩虛證）患者的對比研究[D];福建中醫(yī)藥大學(xué);2015年

2 張容軒;艾迪注射液和鉑類治療惡性胸腔積液的Meta分析[D];蘭州大學(xué);2015年

3 趙華葉;艾迪注射液對順鉑的藥代動力學(xué)及順鉑所致肝腎毒性的影響研究[D];北京中醫(yī)藥大學(xué);2016年

4 王小培;艾迪注射液聯(lián)合TP方案治療晚期NSCLC的臨床觀察[D];湖北中醫(yī)藥大學(xué);2016年

5 黎偉;艾迪注射液聯(lián)合紫杉醇化療對兔舌VX-2鱗癌模型調(diào)節(jié)性T細(xì)胞的影響[D];遵義醫(yī)學(xué)院;2017年

6 聞?wù)?艾迪注射液及其聯(lián)合紫杉醇化療對兔舌VX-2鱗癌模型血管生成及淋巴轉(zhuǎn)移的影響[D];遵義醫(yī)學(xué)院;2017年

7 王明雪;艾迪注射液對兔舌VX-2鱗癌化療模型外周血中Th1/Th2平衡的影響[D];遵義醫(yī)學(xué)院;2017年

8 趙亞娟;艾迪注射液對放射性肺損傷防護作用的臨床研究[D];承德醫(yī)學(xué)院;2013年

9 徐潔;艾迪注射液藥物相互作用研究[D];南京中醫(yī)藥大學(xué);2013年

10 馬明;艾迪注射液對惡性腫瘤患者機體免疫及生活質(zhì)量的影響[D];天津醫(yī)科大學(xué);2010年

，

本文編號：1475108